Efficacy, Safety and Tolerability of PrasugrEl 5mg or TIcagrelor 60mg in COmplex and Higher-Risk Indicated PCI/PatieNts: The Prospective, Randomized, Open-labeled, Blinded Endpoint (PROBE), Multi-center E5TION Trial
Latest Information Update: 05 Jan 2023
At a glance
- Drugs Prasugrel (Primary) ; Aspirin; Ticagrelor
- Indications Coronary artery disease
- Focus Adverse reactions
- Acronyms E5TION; PROBE
Most Recent Events
- 20 Jun 2020 New trial record